Ursodeoxycholic acid

Ursodeoxycholic Acid: A Comprehensive Guide for Patients in Australia

Basic Product Information

Mechanism of Action

For Everyone: Ursodeoxycholic acid (UDCA) is a bile acid, naturally found in your body in small amounts. It works by making bile (a digestive fluid from the liver) less toxic and easier to flow. This helps dissolve certain types of gallstones and protects your liver from damage caused by unhealthy bile.

For Specialists: Ursodeoxycholic acid reduces the concentrations of toxic hydrophobic bile acids, stabilises hepatocyte canalicular membranes, and upregulates biliary secretion via the stimulation of bile acid transporters (such as BSEP and MRP2). In chronic cholestatic diseases, it delays fibrosis and decreases cholestasis-induced apoptosis.

Pharmacokinetics

• Absorption: Well absorbed from the small intestine after oral administration (~60–80%).
• Metabolism: Undergoes enterohepatic circulation; metabolised in the liver to conjugated forms (taurine, glycine derivatives).
• Elimination: Mainly excreted via bile, small amounts in urine (<1%).
• Duration of Action: Half-life is 3.5–5.8 days; remains active as long as daily dosing is continued.

Use in Everyday Life and Best Practices in Australia

Ursodeoxycholic acid is often prescribed for conditions such as primary biliary cholangitis (PBC), certain types of gallstones (particularly cholesterol stones), and some chronic liver disorders. Adults typically take UDCA once or twice daily, depending on the condition. It's important to take it as prescribed and at the same time each day for best results.

• Typical adult dose for dissolving gallstones: 8–10 mg per kg of body weight per day, divided into 2 or 3 doses.
• For primary biliary cholangitis: usual recommended dose is 13–15 mg/kg/day in divided doses.
• Pediatric dosing varies by weight and indication—follows specialist guidance.
• For other off-label uses (e.g., cholestasis of pregnancy, cystic fibrosis liver disease), dosing is adjusted individually.

Dosing in the Morning vs Evening

• Morning Dosing: May align with digestive activity. Some patients find it easier to remember morning medications.
• Evening Dosing: May improve gallstone dissolution as overnight fasting concentrates bile.
• General Tip: Consistency is key. Take at the same time(s) each day.
• Divided Doses: If prescribed more than once daily, space doses evenly (e.g., breakfast and dinner).

Taking with Food or on an Empty Stomach

• With Food: Taking with meals may improve absorption and reduce stomach discomfort. A typical balanced English/Australian diet (including healthy fats from fish, nuts, and olive oil) is suitable.
• Empty Stomach: Absorption may be reduced and may increase gastrointestinal side effects for some patients.
• Recommendation: Take during or just after a meal unless directed otherwise by your doctor or pharmacist.
• Alcohol: Minimise alcohol intake while on UDCA, especially if you have liver disease.

Interaction Warnings

Indications

Dosing According to Clinical Indications

Safety Profile and Side Effects

• Common Side Effects:
  • Diarrhoea
  • Abdominal pain or discomfort
  • Nausea
  • Headache
• Rare or Serious Side Effects:
  • Severe allergic reactions (rash, swelling, difficulty breathing)
    (Seek urgent medical care)
  • Worsening of liver function tests
  • Gallstone calcification or obstruction (if stones do not dissolve)
• Warnings:
  • Do not use if you have complete biliary obstruction or acute gallbladder inflammation.
  • Regular liver function tests recommended during long-term therapy.

Guidelines for Proper Use (Pharmacy & Clinic Advice)

• Take exactly as prescribed; do not adjust the dose yourself.
• If you miss a dose, take it as soon as you remember; if it's nearly time for your next dose, skip the missed one.
• Do not stop treatment without your doctor’s guidance, especially in chronic conditions.
• Keep all appointments for blood tests and reviews.
• Inform other healthcare providers that you are taking UDCA, particularly before surgery or if starting new medications.
• Discuss alcohol use and diet with your healthcare team for best results in managing your liver health.
• Store UDCA in a cool, dry place below 25°C, out of reach of children.

Alternative Treatment Options

• Surgical removal of gallstones (cholecystectomy): First-line for many patients with symptomatic gallstones.
• ERCP (Endoscopic Retrograde Cholangiopancreatography): For certain bile duct stones or strictures.
• Obeticholic acid: For PBC patients unresponsive to UDCA (specialist, PBS eligibility).
• Bezafibrate: Sometimes used for cholestatic liver disease (off-label in Australia).
• Supportive care and other symptomatic therapies: e.g., antihistamines for itching, vitamin supplementation.

UDCA remains the gold standard for most cholestatic liver diseases. Surgical and endoscopic interventions are preferred for gallstone complications or where medical therapy fails. Discuss your treatment options with your gastroenterologist or liver specialist.

Legal, Registration, and Reimbursement Status in Australia

• Regulated by TGA (Therapeutic Goods Administration).
• Available as a prescription-only medicine (Schedule 4, S4).
• UDCA products (e.g., Ursofalk) are reimbursed on the PBS (Pharmaceutical Benefits Scheme) for specific indications (PBC, certain gallstone cases).
• Not available over-the-counter; must be prescribed by a doctor in Australia.
• Private health insurers may cover off-label use in some cases. Discuss with your provider about affordability.

Latest Research & Clinical Guidance (2022–2025)

• PBC Management: 2023 guidance (Gastroenterological Society of Australia, EASL) confirms UDCA as first-line for primary biliary cholangitis, improving survival and delaying the need for liver transplantation (GESA, EASL 2022).
• Pregnancy: Recent studies (Lancet Gastroenterol Hepatol 2023) support continued use in cholestasis of pregnancy for maternal symptom control and possible fetal benefit, though strict monitoring is required.
• PSC & Other Uses: UDCA’s benefits in primary sclerosing cholangitis remain limited; high doses (>20 mg/kg) are not recommended due to lack of efficacy and higher adverse events.
• Combination therapies: Obeticholic acid and bezafibrate are under investigation; combination treatment may offer better biochemical response for PBC non-responders (EASL 2022/2024, GESA 2022).
• References:
  • GESA. Management of liver diseases in Australia. Updated guidelines 2023–2024.
  • EASL. Clinical practice guidelines on PBC and PSC, 2022/2024.
  • Lancet Gastroenterol Hepatol 2023; 8(4): 312-322.

Availability and Delivery

*Prices are indicative and may vary across pharmacies and with insurance status. Delivery times reflect orders placed during business hours.

FAQ – Frequently Asked Questions

• Will this medicine dissolve all types of gallstones?
  No, ursodeoxycholic acid is effective mainly for non-calcified cholesterol gallstones. Pigment or calcified stones, and very large stones, usually do not dissolve with UDCA.
• Can I drink alcohol while taking UDCA?
  It's safest to limit or avoid alcohol—especially if you have liver disease, as alcohol can worsen liver function. Always consult your doctor for personalised advice.
• How long will I need to take UDCA?
  Duration depends on your condition. For PBC, treatment is often long-term, sometimes lifelong. For gallstones, the course is usually 6–24 months. Your doctor will review progress with regular check-ups.
• What if I become pregnant while on UDCA?
  Tell your doctor as soon as possible. UDCA may be continued in pregnancy under close specialist supervision for certain liver/bile conditions. All medication in pregnancy should be carefully discussed with your healthcare team.
• Can children take UDCA?
  Yes—paediatric dosing is determined by weight and condition, usually supervised by a paediatrician or liver specialist.

Always consult your doctor, pharmacist, or liver specialist for advice tailored to your specific health status. This information is a general guide and may not cover every aspect of your individual needs.